Patient-Based Therapeutics

Many scientists believed a single, effective treatment for all patients wouldn't be possible, instead focusing on genetic forms of disease, but AcuraStem is showing how it can be done.

News & Events

June 3, 2024

AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced the expansion of its team with three new team members, bringing a fresh influx of expertise to its pioneering platform.

» Read more
February 27, 2024

AcuraStem’s Head of Target Validation, Dr. Wen-Hsuan Chang, presented an update on the company's innovative UNC13A program at the 14th Annual California ALS Research Summit on January 19, 2024

» Read more
January 30, 2024

AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial

» Read more
September 25, 2023

Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase

» Read more
June 15, 2023

AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, is pleased to announce its sponsorship of the Gordon Research Seminar and Conference on "Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases Mechanisms, Modeling and Translational Therapeutics."

» Read more
March 20, 2023

AcuraStem’s progress in advancing an antisense oligonucleotide (ASO) targeting PIKFYVE and development of therapeutic candidates targeting SYF2 in preclinical studies has been featured in a newly posted BioSpace article.

» Read more
March 20, 2023

A recent study published in the journal Cell Stem Cell and co-authored by AcuraStem CEO Sam Alworth, M.S., MBA, and AcuraStem co-founder Justin Ichida, Ph.D., et al., shows that suppressing the gene encoding spliceosome-associated factor SYF2 may alleviate symptoms of Amyotrophic Lateral Sclerosis (ALS) and improve neuron survival in both sporadic and genetic forms of the disease.

» Read more
January 20, 2023

AcuraStem announced today that CEO Sam Alworth, will present on the company’s latest advances in the development of a PIKFYVE antisense oligonucleotide (ASO) therapeutic for diverse forms of ALS and FTD at the 13th annual California ALS Research Summit

» Read more
December 5, 2022

Dr. Wen-Hsuan Chang, AcuraStem’s Head of Target Validation to present at the 33nd International Symposium on ALS/MND being held virtually on December 6-9, 2022. Dr. Chang will detail AcuraStem’s development program leveraging its best-in-class  iNeuroRx® platform, composed of patient-derived disease models that accurately recapitulate UNC13A pathology, to develop novel and potent UNC13A antisense oligonucleotide (ASO) drug candidates. UNC13A is one of the most significant genetic risk factors for ALS and FTD.

» Read more
December 15, 2021

AcuraStem (acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients. The data were presented at the Motor Neuron Disease Association 32nd International Symposium on ALS/MND on December 9, by AcuraStem’s Head of Research, Wen-Hsuan Chang, Ph.D.

» Read more
December 6, 2021

AcuraStem will present posters at the 32nd International Symposium on ALS/MND.

» Read more
June 28, 2021

The CMT Research Foundation today announced it has partnered with AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, to test a new drug to fight  CMT4B1. Dr. Alessandra Bolino, who will lead the research and testing, is a renowned expert in CMT and head of the Human Inherited Neuropathies Unit at the prestigious research hospital Ospedale San Raffaele in Milan. 

» Read more
May 25, 2021

AcuraStem has received an Amyotrophic Lateral Sclerosis Research Pro-gram (ALSRP) Therapeutic Development Award from the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) totaling $1 million.

» Read more
September 21, 2020

“We are excited to add our collaborator Dr. Robert Bowser to our advisory board. Bob is a worldwide leader in ALS biomarker development. His expertise will be critical as we look to validate key, CNS-specific, mechanistic biomarkers for our PIKFYVE programs,” said Sam Alworth, co-founder and chief executive officer of AcuraStem.

» Read more
November 7, 2019

AcuraStem was honored to once again partner with Team Nanci and the ALS Association Golden West Chapter in the fight against ALS as a sponsor of the 17th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 3, at Exposition Park in Los Angeles.

» Read more
October 22, 2019

AcuraStem announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).

» Read more
January 15, 2019

MDA has awarded an MVP grant totaling $300,000 over two years to AcuraStem to support preclinical development of a novel small molecule therapeutic for ALS.

» Read more
December 20, 2018

CMT Research Foundation announced today it has entered into a collaborative research partnership with AcuraStem to test thousands of compounds aimed at producing effective treatments for Charcot-Marie-Tooth disease.

» Read more
November 2, 2018

AcuraStem will join in the fight against ALS as a sponsor of the 16th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 4, at Exposition Park in Los Angeles. The team will walk with “Team Nanci” and be on hand at the AcuraStem booth to talk to patients and families affected by Amyotrophic Lateral Sclerosis (ALS) about its mission and research underway.

» Read more
August 30, 2018

AcuraStem has announced the members of its Scientific Board of Advisors comprised of PhDs, professors, tech entrepreneurs, and successful drug company veterans.

» Read more
July 27, 2018

AcuraStem announces the addition of Monica Zhou, Ph.D. to their team as Principal Scientist. Zhou is in charge of industrializing the expansion of AcuraStem’s groundbreaking iNeuroRx platform and its multiple applications, ensuring their accuracy and efficiency.

» Read more
June 18, 2018

AcuraStem a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a $3.7 million Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, “AS2015”, focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72.

» Read more
May 22, 2018

AcuraStem is pleased to announce that it has been selected as a finalist in the 2018 Start-Up Stadium event at the BIO International Convention, June 4-7 in Boston.

» Read more
December 4, 2017

The award recognizes Dr. Ichida's "pioneering work to convert patients’ skin cells into disease-affected neural cells, enabling them to screen thousands of drug-like compounds in search of potential therapeutics that could slow or stop ALS."

» Read more
December 1, 2017

AcuraStem has been awarded a $225 thousand Phase I SBIR grant by the National Institute on Aging (NIA), part of the National Institutes of Health. The grant will fund continued research of AcuraStem’s laboratory models of age-associated ALS, supporting the evaluation of different molecular methods to create motor neurons in the laboratory that more accurately reproduce the ALS disease state in aged patients.

» Read more
November 16, 2017

The Governor’s Office of Business and Economic Development (GO-Biz) announced that the California Competes Tax Credit (CCTC) committee approved $69 million in tax credits for 90 companies projected to create 6,236 jobs and make $1.2 billion worth of new capital equipment investments across California.

» Read more